ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0653

JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro

Hiroshi Kajiyama1, Yoshimi Aizaki2, Hiroaki Yazawa3, Kazuhiro Yokota3, Yasuto Araki2, Yuji Akiyama2 and Toshihide Mimura4, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Yokohama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, 3Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan

Meeting: ACR Convergence 2022

Keywords: Cell Death, Drug toxicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Hydroxychloroquine (HCQ) is an anti-malarial medicine and an immunomodulator to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clinical beneficial evidence of HCQ includes anti-thrombotic effects, anti-arthritic effects seen in short term, and disease-stabilizing effects to inhibit the relapse of SLE, renoprotective effect, better life prognosis as long-term effects. On the other hand, there are also non-negligible adverse effects of HCQ such as retinal and renal toxicity. It is known that HCQ cellular cytotoxicity is exerted by inhibiting autophagy and lysosomal enzymes. However, it still remained to be clarified how interference of lysosomal-autophagy pathway by HCQ leads to cellular cytotoxicity. Janus kinase (JAK) was previously reported to be involved in lysosome biogenesis in visceral glomerular epithelial cells (podocytes), hence we pursuit the possibility that JAK inhibitors (JAKis) could reduce cellular cytotoxicity of HCQ in vitro in this study.

Methods: Luminescent-based cell viability plate assay (CellTiter-GloⓇ Luminescent Cell Viability Assay, Promega, USA) was employed to quantify HCQ-induced cell death. Human retinal pigment epithelial cell line (ARPE-19), mouse podocyte cell line (AI), and human podocyte cell line (BLAK) were used as HCQ-induced retinopathy and nephropathy in vitro models to test HCQ cellular toxicity. ARPE-19 was plated on non-coated 96 well plates and AI and BLAK were plated on collagen 1-coated 96 well plates (day 1). ARPE-19 was pretreated with a series concentrations of upadacitinib, and AI and BLAK were pretreated with a series concentrations of baricitinib for 48 hours (day 3, 4). On Day 5, 10 to 80 μg/mL of HCQ was added to these cell lines to induce cell death, and the culture was continued for 4 to 9 days, until cells were subject to viability assay. One-way ANOVA was done using Prism 9 for macOS for statistical analysis.

Results: A series of HCQ concentrations ranging from 0.009 to 80 μg/mL were tested to decide the most appropriate concentration to kill cells, resulting in 80 μg/mL for ARPE-19, 10 μg/mL for AI and 20 μg/mL for BLAK. Upadacitinib at the concentration of 16 nM~10 μM siginificantly inhibited 80 μg/mL HCQ-induced ARPE-19 cell death (Figure 1A). In AI and BLAK (Figure 1B and 1C), 2 to 50 μM of baricitinib significantly inhibited 10 μg/mL and 20 μg/mL HCQ-induced cell death, and protective trend was also seen in the lower concentrations such as 16, 80 and 400 nM of baricitinib. Maximam plasma concentration (cMAX) of 8 mg baricirinib in adults is 107 ng/mL (280 nM), and that of 15 mg upadacitinib in adults is 61 ng/mL (156 nM). JAKi protective effects on HCQ cellular toxicity in these experiments were observed at the clinically-relevant concentration less than cMAX of each JAKi tested.

Conclusion: JAKis counteract celluar cytotoxicity of HCQ in a human retinal pigment epithelial cell line, a mouse podocyte cell line and a human podocyte cell line in vitro. JAK inhibitors might reduce the incidence of retinopathy and that of nephropathy in patients treated with HCQ.

Supporting image 1

Figure 1 Luminescence-based cell viability plate assay. (A) human retinal pigment epithelial cells (ARPE_19), (B) mouse podocytes (AI), (C) human podocytes (BLAK). Abbreviations in the X axis: Dm DMSO, PBS phosphate buffered saline, H Hydroxychloroquine, Up upadacitinib, B baricitinib.
Abbreviations in the Y axis: RLU relative light unit. Asterisks statistically significant in one-way ANOVA, P<0.01.


Disclosures: H. Kajiyama, None; Y. Aizaki, None; H. Yazawa, None; K. Yokota, None; Y. Araki, None; Y. Akiyama, None; T. Mimura, None.

To cite this abstract in AMA style:

Kajiyama H, Aizaki Y, Yazawa H, Yokota K, Araki Y, Akiyama Y, Mimura T. JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/jak-inhibitors-counteract-cellular-toxicity-of-hydroxychloroquine-in-vitro/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/jak-inhibitors-counteract-cellular-toxicity-of-hydroxychloroquine-in-vitro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology